The State Institute of Applied Chemistry (GIPH), part of Rostec State Corporation, has developed a technology to produce raw materials for anesthetic agent sevoflurane. The substance was not produced in Russia before. This drug is used for general and local anesthesia in surgery and dentistry, as well as to provide care to patients affected in extreme situations. The technology will enable pharmaceutical companies to produce the drug in Russia and overcome the dependence on imported supplies.
Sevoflurane belongs to halogenated agents for inhalation anesthesia and is often administered in a mixture with nitrous oxide and oxygen. This anesthetic agent is one of those with the rapid action.
The drugs of the group to which sevoflurane belongs are highly efficient, manageable, and do not have a negative effect on internal organs. All that guarantees safe use.
“Currently, sevoflurane is widely used in medical practice but has not been produced in Russia. Our technology allows to obtain the anesthetic in the form of a technical substance for further production of the finished dosage form at the licensed pharmaceutical companies. We are ready to provide the pharmaceutical industry with at least 50 tons per year of raw materials for the production of sevoflurane. Today it is critically important for the country to minimize the dependence on external supplies of medicines, and our development helps to get closer to this goal,” said Yelena Kozlova, CEO of the State Institute of Applied Chemistry.